ALMÁŠI, Martina, L. BESSE, Lucie BROŽOVÁ, Jiří JARKOVSKÝ, Renata BEZDĚKOVÁ, Luděk POUR, J. MINARIK, P. KESSLER, P. PAVLICEK, L. ROZIAKOVA, Miroslav PENKA, Roman HÁJEK, Anna VAŠKŮ and Sabina ŠEVČÍKOVÁ. Selected Genetic Polymorphisms Associated with Hypoxia and Multidrug Resistance in Monoclonal Gammopathies Patients. Klinická onkologie. Praha: Ambit Media, 2018, vol. 31, No 3, p. 213-229. ISSN 0862-495X.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Selected Genetic Polymorphisms Associated with Hypoxia and Multidrug Resistance in Monoclonal Gammopathies Patients
Name in Czech Vybrané genetické polymorfizmy asociované s hypoxií a multilékovou rezistencí u pacientů s monoklonálními gamapatiemi
Authors ALMÁŠI, Martina (203 Czech Republic), L. BESSE (756 Switzerland), Lucie BROŽOVÁ (203 Czech Republic, belonging to the institution), Jiří JARKOVSKÝ (203 Czech Republic, belonging to the institution), Renata BEZDĚKOVÁ (203 Czech Republic), Luděk POUR (203 Czech Republic, belonging to the institution), J. MINARIK (203 Czech Republic), P. KESSLER (203 Czech Republic), P. PAVLICEK (203 Czech Republic), L. ROZIAKOVA (703 Slovakia), Miroslav PENKA (203 Czech Republic), Roman HÁJEK (203 Czech Republic), Anna VAŠKŮ (203 Czech Republic, belonging to the institution) and Sabina ŠEVČÍKOVÁ (203 Czech Republic, guarantor, belonging to the institution).
Edition Klinická onkologie, Praha, Ambit Media, 2018, 0862-495X.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30205 Hematology
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
RIV identification code RIV/00216224:14110/18:00103521
Organization unit Faculty of Medicine
Keywords in English multiple myeloma; hypoxia; genotype; polymorphism; qPCR
Tags EL OK, rivok
Tags International impact, Reviewed
Changed by Changed by: Soňa Böhmová, učo 232884. Changed: 13/3/2019 13:52.
Abstract
Background: Adaptive response to hypoxia is regulated by several mechanisms and transcription factors, including hypoxia-inducible factors (HIFs). Activation of HIF-1alpha is associated with increased expression of P-glycoprotein and multidrug resistance in cancer cells. In this retrospective study, we analyzed candidate single-nucleotide polymorphisms (SNPs) in HIF-1alpha and HIF-1beta associated with risk of monoclonal gammopathy of undetermined significance (MGUS) or multiple myeloma (MM). Patients and Methods: Genotypes of SNPs associated with hypoxia were determined in an independent cohort of monoclonal gammopathies (MG) (275 MM and 228 MGUS patients) and in 219 cancer-free controls by real time polymerase chain reaction allelic discrimination. Results: When MM patients were compared to controls, protective role of CG genotype compared to CC in HIF-1beta (rs2228099) for MM development was observed (OR = 0.65; CI 0.45-0.95; p = 0.026). Even after adjustment for patients' age and body mass index (BMI), there were significantly lower odds (OR = 0.55; p = 0.045) of developing MM patients of CG genotype in comparison to CC genotype. Log-rank test confirmed association of GT haplotype (rs11549467, rs2057482) in HIF-1alpha with better overall survival (median 41.8 months; (CI 35.1-48.5)) for "none GT" and median 93.8 months (CI 31.3-156.4) for "at least one GT" haplotype (p = 0.0500). Further, significant associations between SNPs in MDR1 and outcome of MM were found in 110 MM patients that underwent bortezomib-based treatment. Conclusion: Our study showed a genetic predisposition for risk of MG development and/or outcome of MM patients; nevertheless, further studies are needed to confirm our initial analysis.
PrintDisplayed: 25/4/2024 09:21